Long-term efficacy assessment of current treatment options for epistaxis in HHT. by Dür, Cilgia et al.
Vol.:(0123456789) 
European Archives of Oto-Rhino-Laryngology 
https://doi.org/10.1007/s00405-021-06701-z
RHINOLOGY
Long‑term efficacy assessment of current treatment options 
for epistaxis in HHT
Cilgia Dür1  · L. Anschuetz1 · S. Negoias2 · O. C. Bulut3 · A. Angelillo‑Scherrer4 · M. Caversaccio1
Received: 25 October 2020 / Accepted: 9 February 2021 
© The Author(s) 2021
Abstract
Purpose Hereditary hemorrhagic telangiectasia (HHT) is a vascular disorder that presents with recurrent, intractable 
epistaxis. The aim of this study was to retrospectively analyze the efficacy of various treatment options for epistaxis in 
patients with HHT, over a period of 18 years, and to correlate these findings with available evidence in the literature.
Methods Records of patients with HHT, treated for epistaxis between 2000 and 2018 were analyzed. Treatment procedures 
carried out and their efficacy were extracted and analyzed.
Results Forty-three records were evaluated. All patients were given nasal humidifying ointments, 93% required acute treat-
ment with bipolar electrocautery, and 60% underwent atraumatic nasal packing. Recurrent cases were treated medically with 
tranexamic acid (26%), oestrogen (19%), and bevacizumab (2%). Laser photocoagulation was done in selected cases (40%) 
and if unsuccessful, septal dermoplasty was performed (2.3%). Endovascular embolization was reserved for life-threatening 
emergencies (7%).
Conclusion Epistaxis in HHT is not curable, but can be managed by employing a comprehensive stepwise approach. An 
algorithm for effective and comprehensive management has been presented.
Keywords Rhinology · Epistaxis · Hereditary hemorrhagic telangiectasia · Rendu-osler · Laser photocoagulation · 
Bevacizumab
Introduction
Hereditary haemorrhagic telangiectasia (HHT), also known 
as Osler–Weber–Rendu disease, is a rare autosomal domi-
nant disorder causing angiodysplasia. It occurs in one of 
every 5000 persons, and is believed to be underdiagnosed 
[1]. In HHT, capillaries of the skin, mucous membranes, and 
specific organs such as lungs and liver are absent, and there 
is direct communication between the dilated arteries and 
veins. This causes extreme fragility of the vessels, which can 
rupture at even the slightest trauma. This is clinically visible 
as mucosal or cutaneous telangiectasias and arteriovenous 
malformations.
Epistaxis is the most common clinical manifestation 
of HHT. At least one episode occurs by 12 years of age in 
most patients, often before the disease has been diagnosed. 
It occurs in almost all patients by 40 years of age. More than 
50% of patients suffer from recurrent epistaxis before the age 
of 20, which becomes more severe in later decades. By the 
age of 40, epistaxis frequently occurs in almost all patients 
with HHT [1]. The frequency and severity of epistaxis often 
leads to iron deficiency anaemia, requiring multiple blood 
transfusions. This has a negative impact on the quality of 
life [2].
Several treatment options have been described in the 
literature [3–9]. Medical modalities of treatment range 
from simple humidification to use of complex drugs 
like thalidomide [3, 4] and bevacizumab [5, 6]. Surgical 
options have, included septal dermoplasty [7], endovascu-
lar embolization [8], and even complete nasal closure [9]. 
None of the treatment methods have proved to be complete 
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solutions. Resistance has been noted to several medical 
treatments, and surgical treatment does not necessarily 
improve quality of life. Therefore, the ideal treatment 
option has yet to be identified.
With this background, we aim to add the existing body 
of literature on the management of epistaxis in HHT by 
retrospectively analysing different treatments carried out 
for epistaxis in HHT patients. We attempt to correlate 
these findings with literature evidence to identify the best 
protocol to be followed in such patients.
Methods
This study was approved by the institutional and regional 
review board (Inselspital, University Hospital Bern, Bern, 
Switzerland, KEK-No. 201-00743). Owing to the retro-
spective nature of the study, formal written informed con-
sent was not required.
The data of all patients treated in the ENT department 
of the University Hospital in Bern between 2000 and 2018 
were retrospectively analysed. Records of patients who 
appeared to have HHT were included for analysis. Patients 
were considered to have HHT if they had satisfied at least 
3 of 4 of the Curaçao criteria [10] (Table 1).
The information extracted from the records, included 
clinical notes from consultations, operations, and radio-
graphic examinations. Epidemiological data and the pres-
ence of anaemia and need for transfusion, septal perfo-
rations, screening for arteriovenous malformations, and 
genetic testing were noted. The various medical and surgi-
cal treatment modalities employed were recorded for each 
patient as well as the time to bleeding following each treat-
ment modality. The extent of follow-up after treatment 
was checked.
Results
A total of 51 records of patients suffering from HHT were 
obtained. Complete records were available for 43 patients, 
and these were analysed. Of these 43 patients, 22 were male 
(51%) and 21 female (49%). The average age at diagnosis 
was 45 years. Among these patients, 28 (65%) suffered from 
iron deficiency anaemia due to chronic bleeding. Owing to 
the anaemic status, 17 patients (40%) required blood transfu-
sions at least once.
Acute episodes
All 43 patients had visited the emergency department at least 
once due to severe epistaxis. Acute management of epistaxis 
was performed in 40 patients (93%) using bipolar electri-
cal coagulation. Twenty-six patients (60%) underwent nasal 
packing using lubricated and ensheathed packs. Episodes 
leading to hospitalization were present in 24 patients (56%). 
Three patients (6.9%) underwent embolization, and one of 
them (2.3%) received septal dermoplasty.
Long‑term management
For prevention of bleeding in the long term (chronic man-
agement), conservative medical management was tried first. 
If that was not successful in terms of reducing the frequency 
and severity of bleeding events, then surgical modalities 
were employed.
Conservative medical management
All patients were advised to use hydrating therapy to keep 
the nasal mucosa humidified. This included saline or lanolin 
and dexpanthenol ointments. Eight patients (19%) received 
oestrogen-containing ointment. One patient (2%) was treated 
with a locally administrated bevacizumab. Eleven patients 
(26%), who had developed anaemia due to chronic bleeding, 
were prescribed oral doses of tranexamic acid ranging from 
500 to 1000 mg, one to three times a day.
Surgical therapy
In patients who did not respond to medical management, 
surgical treatment was carried out. Laser photocoagulation 
was performed in 17 cases (40%). Of these, 13 patients 
(30%) underwent a Nd:YAG laser treatment and four 
patients (9%) underwent Argon or CO2 laser treatment. 
Seven of the laser-treated patients (16%), who required 
two or greater than two sessions, were considered as repeat 
patients. Of these, six patients required repeat Nd:YAG 
Table 1  Curaçao’s criteria for HHT diagnosis
Source: Shovelin et al. [10]
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laser, and one required repeat Argon laser treatment. Four 
patients (10%) developed septal perforation.
In the three patients who underwent embolization, the 
facial, maxillary, or sphenopalatine artery was addressed. 
Two patients required this procedure more than once. One 
of these patients, who underwent embolization three times, 
had been receiving bevacizumab therapy previously. The 
other patient had previously received cautery and three 
rounds of laser photocoagulation, which was unsuccessful, 
and subsequently underwent transarterial embolization of 
facial, maxillary, and sphenopalatine arteries. He later also 
received septal dermoplasty and local radiotherapy.
None of the above therapeutic interventions were able 
to completely eliminate bleeding episodes. The duration 
of reduction of the need for hospital visits (both emer-
gency and planned visits), due to a severe bleeding episode 
ranged from none to up to 4 years. The time to hospital 
visits due to bleeding episodes was compared for different 
modalities of treatment using the Kruskal–Wallis test. The 
values were found to be significant (H statistic 12.889, 
p = 0.004).
Figures 1, 2 illustrates the time to bleeding episodes 
after acute and chronic treatment options were employed. 
Most effective results were obtained with Nd:YAG laser, 
either with single or repeat procedures (Table 2).
Adjunctive treatment
Twelve patients (28%) underwent screening in our hospital 
for arteriovenous malformations (AVMs). Seven patients 
(16%) were found to have pulmonary AVMs and one 
patient (2%) had a cerebral AVM. One patient, who had 
juvenile polyposis and HHT (2%), was genetically tested 
and found to have SMAD4 gene mutation.
Discussion
This retrospective study illustrates a variety of options for 
treating epistaxis in HHT patients, representing, to our 
knowledge, the biggest HHT patient cohort in Switzerland so 
far. The present study shows that despite numerous options 
for treatment, epistaxis continues to be a recurrent problem 
in HHT patients. The medical literature provides support for 
the treatment modalities employed as well as for other forms 
of treatment. We have reviewed all the methods used to man-
age epistaxis in HHT patients described in the literature, and 
compared this to the protocols used in our cohort.
Conservative strategies for management 
of epistaxis
For acute management of bleeding, the only conservative 
strategy that can be employed is nasal packing. Nasal pack-
ing is a safe option when bilateral bleeds are present; unlike 
coagulation methods, there is no risk of septal perforation. 
In the current cohort, this was the preferred method for acute 
management of bilateral bleeds. The main disadvantage of 
nasal packing is that their removal at a later date can cause 
re-bleeding. This may be avoided by using pneumatic packs 
or sheathed standard packs. Pneumatic packs allow deflation 
prior to removal, and sheathed packs have a lubricated outer 
covering, which can minimize friction and trauma [11].
For reducing the frequency and duration of episodes, 
humidifying agents remain the first line of treatment for 
epistaxis in HHT patients. These agents can maintain integ-
rity of the nasal mucosa. They prevent nasal crusting and 
reduce damage to the endonasal mucosa, leading to a reduc-
tion of epistaxis [11]. One observational study found that 
using sesame/rose geranium oil showed good efficacy in 
reducing the Epistaxis severity score. This was attributed 














































Fig. 2  Time to re-bleeding following the treatments for chronic recur-
rent bleeding
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[12]. Nasal ointments usually contain lanolin, dexpanthe-
nol, or saline. However, there is a lack of sufficient data to 
recommend one topical therapy over another. In the current 
cohort, humidification was prescribed as the first line treat-
ment for all patients.
Medical therapy for management of epistaxis
Hormonal therapy, including oestrogen and anti-oestrogen 
therapy with tamoxifen, has been used in the past for man-
agement of epistaxis in HHT. Early anecdotal reports sug-
gested that high-dose oestrogen could decrease epistaxis 
frequency [13]. However, a randomized controlled trial by 
Vase et al. indicated that there was no significant difference 
in bleeding between the oestrogen and control group [14]. 
On the other hand, tamoxifen has proven to be successful 
in decreasing the frequency of epistaxis, in case reports, 
as well as in a randomized controlled trial [15, 16]. In our 
cohort, eight (19%) patients received oestrogen-containing 
ointments that were applied topically.
The use of haemostatic agents has also been used to stop 
bleeding episodes. Tranexamic acid, an anti-fibrinolytic 
agent, has been used to treat HHT patients. Geisthoff et al. 
conducted a double-blinded trial evaluating the effect of 
tranexamic acid against placebo [17]. They found that while 
this drug reduced the frequency of epistaxis, the haemo-
globin levels did not change significantly. In our cohort, 11 
patients (26%) received oral treatment with tranexamic acid. 
In patients who are at high risk of developing thromboem-
bolic events, local administration of tranexamic acid may 
be considered. In this cohort, two patients (9.5%) received 
topical application of 5 ml of tranexamic acid nose cream, 
in a concentration of 5 mg/ml.
Propranolol, a beta-blocker, is believed to have an anti-
angiogenic effect. It reduces VEGF expression, and induces 
apoptosis of endothelial cells. Mei-Zahav et al. retrospec-
tively analysed six patients who underwent treatment with 
topical propranolol gel (1.5%), twice daily for 12 weeks [18]. 
They found a significant improvement in epistaxis severity 
score and haemoglobin levels. The number of blood trans-
fusions decreased, but not significantly. Contis et al. also 
analysed the effect of propranolol, taken orally (80–160 mg 
daily), in 21 HHT patients. They found that it decreased the 
intensity and frequency of episodes [19]. Timolol is another 
beta-blocker with similar actions. Ichimura et al. prospec-
tively analysed the effect of topical timolol in 11 patients 
who had already undergone nasal dermoplasty. They found 
marked reduction in the intensity and frequency of bleeding 
[20]. In the current cohort, we did not use beta blockers, 
owing to the paucity of evidence on the subject at the time 
of treatment.
The advent of drugs that inhibit vascular endothelial 
growth factor marked an important step in the management 
of epistaxis in HHT patients. Bevacizumab, a recombinant 
form of monoclonal antibody, binds and inhibits VEGF, and 
thus prevents endothelial cell proliferation and angiogen-
esis. However, in a randomized trial, Whitehead et al. found 
that topical bevacizumab was no different than placebo in 
decreasing frequency of epistaxis [21]. Steineger et al. ana-
lysed intranasal submucosal injections of bevacizumab in 
33 patients [6]. They found that although this treatment was 
effective, it was common to develop resistance to this drug 
at a later stage. Halderman et al. conducted an evidence-
based review of eleven articles that analysed the efficacy of 
this drug in HHT patients [5]. They found that while topical 
administration was ineffective, submucosal and intravenous 
forms appeared to have some effect in controlling epistaxis. 
On the other hand, Stokes et al. systematically reviewed 
thirteen studies that reported either topical or submucosal 
bevacizumab therapy. They stated that both submucosal 
and topical bevacizumab therapy did not have any effect 
on frequency and duration of epistaxis [22]. In the current 
cohort, one patient who had recurrent epistaxis was placed 
on submucosal injections of bevacizumab. In accordance 
with published studies, it was not effective and re-bleed-
ing occurred within a month. However, a recent literature 
Table 2  Average time to 
hospital visit due to bleeding 
with various forms of treatment
Treatment modality Number of interven-
tions
Mean time till bleeding 
(months)
Standard deviation
Treatments for acute bleeding
 Bipolar electrocautery 39 7.4615 5.8076
 Ensheathed packs 26 6.0385 5.1574
 Embolization 3 6.6667 5.0332
Treatments for chronic recurrent bleeding
 Nd:YAG laser 13 16.6154 12.7249
 Repeat Nd:YAG 6 14.667 13.35
 Argon laser 4 10.25 7.2284
 Repeat Argon 1 24 –
 Bevacizumab 1 1 –
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review has supported the use of intravenous bevacizumab 
for patients with severe epistaxis. This was not attempted in 
our case series; but, based on evidence from the literature, 
it may be considered as a treatment option [23].
Pazopanib is another VEGF inhibitor that targets the 
enzyme tyrosine kinase. Not much has been reported regard-
ing the use of this drug in HHT. Parambil et al. have reported 
the use of this drug in a 61-year-old male with HHT refrac-
tory to bevacizumab. The patient showed improvement in 
the severity of epistaxis with pazopanib, taken at 50 mg/day 
[24]. The dose was increased and maintained at 100 mg/day. 
This is a new drug and can be tried in the future for HHT 
patients who become resistant to bevacizumab.
Thalidomide is also known to inhibit angiogenesis. Fang 
et al. evaluated its use in seven HHT patients who had refrac-
tory recurrent epistaxis. Patients were evaluated using the 
epistaxis severity score (ESS), and they showed improve-
ment in symptoms one to three weeks after the treatment had 
started. However, there were several side effects, including 
dizziness, drowsiness, nausea, constipation, and periph-
eral neuropathy [3]. Baysal et al. also evaluated its use in 
six patients [4]. They found improvement in both ESS and 
SF-36 scores, the latter evaluates quality of life. They did 
not observe notable side effects. Thalidomide was not used 
in the current cohort.
Surgical and interventional therapy 
for management of epistaxis
When conservative approaches and medical therapy fail, 
several minimally invasive as well as open surgical pro-
cedures are available to reduce the frequency and sever-
ity of epistaxis in HHT patients. In the current study, this 
was required in 40% of patients when medical management 
failed.
For acute management of epistaxis, coagulation of blood 
vessels is the preferred method. This may be achieved either 
by bipolar cautery, or laser photocoagulation. Endonasal 
coagulation with bipolar cautery is immediately effective 
and seals off the ruptured vessel immediately. Ghaheri et al. 
reported its use in 47 patients, and they stated that it was 
effective in controlling epistaxis, either as a standalone 
method, or as an adjunct to laser coagulation [25]. In the 
present cohort, bipolar cautery was used for management 
of acute unilateral bleeds only, to minimize the risk of sep-
tal perforation. However, we found that the use of bipolar 
cautery was associated with faster return to the hospital with 
nasal bleeds.
Laser photocoagulation can destroy defective blood ves-
sels with minimal injury to the surrounding normal mucosa 
[26]. It causes scarring and fibrosis, which lead to a decrease 
in telangiectasias. The effect is often time-limited and the 
procedure has to be repeated. Several laser devices with 
different wavelengths (ND:YAG, KTP, Argon, CO2) can 
potentially be employed. Abiri et al. reviewed fifteen stud-
ies that had employed different kinds of lasers for controlling 
epistaxis in HHT patients. They concluded that Nd:YAG 
and argon lasers showed better results as compared to argon 
lasers. For severe epistaxis, Nd:YAG lasers were superior 
to argon lasers [27]. In the present cohort, more favourable 
long-term results were achieved with the use of ND:YAG 
laser. Although this was preferred used in patients because 
of its greater depth of penetration, ND:YAG laser does have 
its drawbacks. It cannot be used to control acute bleeding, 
and bilateral coagulation carries the risk of septal perfo-
ration. Septal perforation was seen in four patients in this 
study, but in these cases, the risk could have been potentiated 
by previous remedies such as bipolar cautery.
Radiofrequency coblation is an acceptable alternative to 
laser coagulation. This breaks down molecules into inert 
gases at comparatively lower temperatures, so the risk of 
thermal injury to tissues is less. Joshi et al. used coblation 
in five patients and found that it was safe, effective and well-
tolerated [28]. Luk et al. also found that coblation was an 
effective alternative to KTP lasers, and subjects who had 
coblation experienced less nasal obstruction following the 
procedure [29].
A few studies have evaluated the effect of endovascular 
embolization. One study by Trojanowski et al. showed a suc-
cess rate of 85%, but patients also had a high recurrence rate 
of 43% [8]. This therapy is mostly indicated in acute condi-
tions. In the current study, we reserved this procedure for 
acute, life-threatening cases not responding to nasal packing. 
Our patients underwent endovascular embolization of the 
sphenopalatine and/or facial and/or maxillary arteries on one 
or both sides. Most authors do not recommend embolization, 
as it carries a high risk of stroke and blindness, particularly 
if the anterior and posterior ethmoidal arteries are treated at 
the same time.
External radiotherapy was tried in one patient in the pre-
sent cohort, who was found to be refractory to most forms 
of treatment. Both external beam radiotherapy and brachy-
therapy can irreversibly destroy fibrodysplastic microvessels, 
thereby reducing epistaxis. Patients who underwent brachy-
therapy had favourable results with some patients experi-
encing complete remission [30]. External radiotherapy also 
seems to be effective and has been used in palliative settings 
after other treatment options have failed [31]. Both methods 
are associated with a risk of septal perforation. There is also 
a concern that radiotherapy might increase the risk of neo-
plastic transformation of cells.
Sclerotherapy has been used in two studies in the litera-
ture. Injection of sodium tetradecyl sulphate into defective 
vessels can cause scarring and fibrosis and reduce telangi-
ectasias, and therefore, epistaxis. One trial, by Boyer et al. 
showed that sclerotherapy was more effective than several 
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other standard forms of therapy [32]. Another observational, 
cross sectional study was carried out by Esteban-Casado 
et al. [33]. Thirty-eight patients underwent sclerotherapy 
with polydocanol, and received long-term topical nasal pro-
pranolol thereafter. Significant improvements were found 
in both the mean epistaxis severity score and quality of life. 
Further comparative studies are needed to validate this treat-
ment option.
Septal dermoplasty is a procedure which is usually used 
only as a last line of defence. In septal dermoplasty, the 
nasal mucosa is replaced by skin or buccal mucosal graft tis-
sue, while preserving the underlying perichondrium. Harvey 
et al. showed that septodermopasty can reduce the need for 
multiple laser procedures by as much as 57% [7]. However, 
telangiectasias have been found to grow through the skin 
graft, leading to recurrence of epistaxis. This procedure 
can also cause long-term nasal crusting, compounding the 
problem. Therefore, this procedure is more useful in severe 
cases. Nevertheless, the indications have not been clearly 
established in the literature. In the current study, we used 
this as a last resort, only when laser treatment had failed 
at least three times. In a previous study by Lesnik et al., 
the procedure was used in patients who had developed sep-
tal perforation following other treatments. They noted that 
the procedure could improve quality of life in patients with 
transfusion-dependent epistaxis [34].
Nasal closure of one or both sides, also known as Young’s 
procedure, is the only known option which has been shown 
to result in complete cessation of epistaxis. However, this 
has deleterious side effects, including chronic mouth breath-
ing and partial or complete anosmia, which can compromise 
the quality of life. Thomson et al. evaluated the effect of 
nasal closure on quality of life [9]. They found that while 
nasal closure improved the ESS, it did not have a significant 
effect on sleep or quality of life, and must therefore be con-
sidered as a last resort. Another alternative or pre-evaluative 
option before complete nasal closure is the use of a nasal 
obturator. Woolford et al. described the use of a silastic nasal 
obturator in three patients, and observes that the frequency 
of epistaxis reduced on using the obturator [35].
Fig. 3  Proposed algorithm for the management of epistaxis in patients with HHT
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Limitations of the study
One drawback of the study was that the primary outcome 
measure, that is, time until the next visit, is a patient-specific 
measure, dependent on disease severity, which has inter-
individual variability. Although the current study measured 
the time to bleeding following each treatment modality, it 
could not evaluate the particular efficacy of each treatment. 
For this, a randomised prospective trial would be required. 
Based on the evidence available from literature and our own 
experience, we propose an algorithm for the management 
of patients with HHT who present with acute or recurrent 
epistaxis (Fig. 3).
Conclusion
Despite the vast plethora of potential treatments available, 
complete control of epistaxis in HHT patients is difficult to 
achieve without compromising the quality of life. Newer 
treatment options have emerged but need validation. Further 
research is needed with certain forms of therapy, including 
pazopanib therapy and sclerotherapy. In general, it is best 
to begin with conservative and medical management and 
escalate to surgical intervention when needed. The algorithm 
accompanying this article aims to provide a comprehensive 
and stepwise management approach in controlling bleeding 
with minimal impact on patients’ quality of life.
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